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Abstract
The use of antimicrobial agents and acquired resistances explains in part the emergence 
and spreading of epidemic strains of Clostridium difficile. Continued use of antimicrobial 
therapy still represents an acute danger in triggering the emergence and spreading of 
new resistant and multiresistant strains including against first-line antibiotics. We exam-
ine the pathway of peptidoglycan synthesis in this organism and associated resistances, 
as well as resistance to other classes of antibiotics. The life cycle of C. difficile involves 
growth, spore formation and germination. Spores endow the organism with a formidable 
capacity of persistence in the environment and in the host, resistance, dissemination and 
infectious potential. Highly resistant spores produced by antibiotic-resistant/multire-
sistant strains may be one of the most serious challenges we face in what concerns the 
containment of C. difficile. Finally, we review recent developments in the treatment and 
prevention of C. difficile infection.
Keywords: Clostridium difficile infection, antibiotics, epidemiology, drug resistance, 
spores, β-lactam antibiotics, fidaxomycin, Clostridium scindens
1. Clostridium difficile life cycle: antibiotic-resistant spores as infectious, 
persistence and dissemination vehicles
1.1. Clostridium difficile biology
The human gut is the home of a community of as many as 1000 species of commensal, benefi-
cial and pathogenic microorganisms. Recent studies suggest that at least half of the bacterial 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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genera found in the gut produce resilient spores [1]. One of these organisms is Clostridium 
difficile, a Gram-positive spore-forming anaerobe. C. difficile was recently placed in the 
Peptostreptococcaceae family and renamed Peptoclostridium difficile [2] and later Clostridioides 
difficile [3], yet we use herein the still more familiar designation of C. difficile.
Although C. difficile (Bacillus difficile by that time) has been first described in 1935 by Hall and 
O’Toole as part of the bacterial flora of the meconium and faeces of infants [4], it was only 
in 1974 that three independent studies have implicated C. difficile has an important cause of 
disease in humans. These studies also showed that the organism produced a toxin that was 
highly lethal to mice, but the toxicity to humans was not demonstrated. In one of these studies, 
the causal effect of antibiotic exposure and gut disease was demonstrated. The study, con-
ducted by Tedesco and co-authors, found a significant association between patients receiving 
clindamycin and the development of pseudomembranous colitis (PMC), although at this stage 
the etiology of this observation remained unknown [5]. In 1977, C. difficile was isolated from 
the faeces of hamsters with clindamycin-induced colitis, confirming this pathogen as the cause 
of antibiotic-induced disease in animals [6]. In 1978, two studies provided confirmation of the 
causal association of C. difficile infection (CDI) and antibiotic-associated PMC in humans [7, 8].
The original name of C. difficile reflects the difficulties in the isolation and growth of this 
bacterium in the laboratory. Nowadays, we face the problem of being unable to control the 
growth and spreading of this organism. In the last decade, epidemic strains, including those of 
ribotype 027 (RT027), have emerged that caused outbreaks associated with increased disease 
severity and higher recurrence, morbidity and mortality rates, and C. difficile is now consid-
ered the major causative agent of nosocomial diseases associated to antibiotic therapy in adults 
[9–11]. C. difficile causes close to 500,000 infections and 29,000 deaths each year in the United 
States alone, with about 20% of CDI leading to recurrence, and imposing an economic burden 
on the healthcare system estimated at over US$ 1 billion [12, 13] or an estimated €3 billion in 
Europe [14]. C. difficile is categorized as an urgent threat, the highest level of concern, by the 
CDC (Center for Disease Control and Prevention). Moreover, increased rates of community-
associated C. difficile disease, affecting groups not previously at risk, such as children, healthy 
young adults and pregnant women, and zoonotic transmission are a raising concern [11].
1.2. The life cycle
C. difficile is an enteric pathogen that relies on the disturbance of the normal gut microbiota 
to expand in the gut and cause infection; individuals with a normal, balanced microbiota are 
usually resistant to infection by C. difficile [14–16] (see below). Unlike most of the commensals, 
C. difficile resists to a wide range of antibiotics (see below). Resistance to antibiotics such as 
erythromycin, chloramphenicol or tetracycline is largely mediated by transposons that are 
present in the C. difficile genome [17–19]. Individuals with a normal, balanced microbiota are 
usually resistant to infection by C. difficile (see subsequent text). Disease symptoms range 
from mild diarrhoea and abdominal pain to life-threatening inflammatory lesions such as 
PMC, toxin megacolon or bowel perforation, and in severe cases sepsis and death [16, 20, 
21]. These symptoms are mainly caused by two potent proinflammatory cytotoxins, TcdA 
and TcdB, that following release from the bacterium, translocate to the cytosol of target host 
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cells and inactivate, by monoglucosylation, small GTP-binding proteins, including Rho, Rac 
and Cdc42. TcdA and TcdB cause actin condensation, disintegration of the cytoskeleton, cell 
rounding and eventually cell death [22]. These toxins are coded for by two genes, tcdA and 
tcdB, located in the pathogenicity locus (PaLoc) (Figure 1A). The PaLoc also contains three 
additional genes, tcdE, tcdR and tcdC. TcdE is thought to be a putative holin-like protein 
involved in toxin secretion; its impact on toxin secretion, however, is still under debate [23, 
24]. TcdR is an RNA polymerase sigma factor that serves as the main positive regulator of 
expression of the PaLoc and activates its own expression from two tandem promoters [25, 
26] (Figure 1A). Importantly, the expression of tcdR is also activated from a promoter respon-
sive to σD, the main regulatory protein involved in the final stages of flagellar assembly [27] 
(see also below) (Figure 1A). TcdC is thought to be a TcdR-specific anti-sigma factor that 
negatively regulates TcdR-dependent transcription [23, 28, 29]. TcdC was also shown to bind 
DNA, which suggests an alternative function for this anti-sigma factor [30]. Some C. difficile 
strains, as those of RT027 and RT078, also produce a binary toxin known as CDT (C. difficile 
transferase) (Figure 1B). The CDTb component of CTD binds to the host cells and translo-
cates CTDa, that ADP-ribosylates actin, inducing depolymerization of the actin cytoskeleton. 
Toxin-induced actin depolymerization also induces redistribution of microtubules and for-
mation of long microtubule-based protrusions at the surface of the intestinal epithelia cells; 
these protrusions trap the bacteria in small compartments, increasing the adherence of C. 
difficile [31–33]. In mice, by inducing inflammation via a Toll-like receptor 2 (TLR2), CDT sup-
presses a protective colonic eosinophilic response [34].
Figure 1. Schematic representation of the PaLoc (A) and CdtLoc (B) loci of C. difficile. A: This shows the genetic 
organization of the PaLoc in toxinogenic strains, which includes the tcdR, tcdB, tcdE, tcdA and tcdC genes. tcdR codes for 
an RNA polymerase sigma factor that controls expression of the tcdB and tcdA genes and possibly also of tcdE. The main 
promoters in the region are represented by broken arrows. The figure highlight the main regulatory circuits highlighted 
in the text. Transcription of the tcdR gene is governed by at least three promoters, two of which are auto-regulatory (‘+’ 
signs); a third promoter is under the control of σD, the regulatory protein governing the last stages in assembly of the 
flagellum. A promoter recognized by the housekeeping sigma factor σA, located downstream of the σD-type promoter 
has also been proposed [108]. Transcription of tcdR is directly repressed by CodY and CcpA but the latter also represses 
the expression of other PaLoc genes (not shown) [103, 108]. c-d-GMP also represses the expression of the PaLoc by 
inhibiting the production of σD. B: This shows the organization of the binary toxin locus or CdtLoc. cdtR codes for a 
response regulator required for full expression of the downstream genes, cdtA and cdtB, coding for the two components 
of the binary toxin CDT. The putative kinase that activates CdtR is unknown. The CDT toxin is only produced by some 
strains, including those of RT027 and RT078; in some strains, the locus is absent, whereas in others, such as 630∆erm, 
cdtA and cdtB are pseudogenized [33].
Overview of Clostridium difficile Infection: Life Cycle, Epidemiology, Antimicrobial Resistance...
http://dx.doi.org/10.5772/intechopen.69053
7
Since C. difficile is a strict anaerobe, its virulence potential is linked to the ability to form 
spores. Spores are resistant to heat, oxygen and other environmental insults, including com-
monly used ethanol-based disinfectants. When ingested, the spores are able to pass the gastric 
barrier and reach the intestine where they are thought to attach to the epithelial cells in order 
to achieve proper germination, which is induced by certain bile salts (see below) (Figure 2). 
Spore germination and outgrowth, in the absence of a competitive microbiota, will result 
in the establishment of a population of vegetative cells that will expand, produce the TcdA 
and TcdB toxins and eventually more spores (Figure 2). The toxins will cause damage to the 
colonic mucosa and eventually severe diarrhoea; shedding of the spores to the environment 
allows the infection of new hosts (Figure 2) [15, 22, 35, 36].
Spores are the vehicle for transmission as well as for environmental persistence. Mice exposed 
to spores exhibited recurrent infection with the same strain (disease relapse), but a spo0A 
mutant, lacking the key regulatory protein governing entry into sporulation and thus unable 
to form spores, was incapable of recolonization and host-host transmission [37]. Evidence 
suggests that C. difficile forms biofilms in vivo and in vitro and that the main virulence and 
persistence factors (toxins and spores) are produced within these structures [38–40]. In mice, 
infection with C. difficile spores followed by a 7-day period of treatment with clindamycin 
results in entry into a highly contagious period, during which high number of spores are 
shedded [40]. For a RT027 strain, the ‘supershedder’ state remained for months, even after 
Figure 2. Schematic representation of the C. difficile infectious cycle. Spores are ingested and are able to pass the 
gastric barrier to reach the intestine. In the intestine, when the normal gut microbiota is disturbed, as during antibiotic 
treatment, the ratio of the bile salts derivatives cholate (CA) and chenodeoxycholate (CDCA) increases and the spores 
will germinate. C. scindens, for example, produces a 7α-dehydroxylating activity that converts CA into CDCA, blocking 
germination of C. difficile spores (insert). Spore germination, which may occur following recognition of a receptor (R) 
in the colon, and cell outgrowth will eventually produce a population of vegetative, actively growing cells, which will 
initiate toxinogenesis and sporogenesis. The two cytotoxins TcdA and TcdB will cause severe damage to the epithelium 
and are the main direct causes of the disease symptoms. The CDT binary toxin, present in some C. difficile strains, 
as those of RT027, is also represented. Other virulence factors (e.g. the flagellum, the S-layer) are not represented for 
simplicity. Shedding of the highly resistant spores will allow their accumulation into the environment and the infection 
of new hosts. Spores that remain in the host, in an unknown niche, are also the cause of disease recurrence.
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cessation of antibiotic treatment, causing chronic intestinal disease [40]. During this period, 
the bacteria persisted as microcolonies and biofilm-like structures at the surface of the intes-
tinal mucosa [40]. Bacteria within the biofilm are protected and therefore more resistant to 
antibiotics and oxygen [38]; conversely, spores may help shielding the biofilm. While an evo-
lutionary link exists between sporulation and biofilm formation [41], a direct demonstration 
of the role of biofilms in disease and whether C. difficile persist in the intestine after antibiotic 
treatment as a biofilm, spores or both, is, however, lacking. Although the toxins, responsi-
ble for most of the disease symptoms, and spores (as a transmission/persistence factor), are 
the major C. difficile virulence factors [22, 37, 42], other virulence factors include the S-layer, 
fibronectin-binding proteins, flagella, fimbriae and the heat shock protein GroEL (for recent 
reviews, see [10, 11, 43]).
1.3. Spore formation
Spores are arguably the most resilient cellular form known to us; they are hard to eradicate 
and can accumulate and persist in the environment for long periods of time, without losing 
viability [16, 44–46]. The spore thus has a central role in the persistence of the organism in the 
environment, infection, recurrence and transmission of the disease [37].
Two classes of Firmicutes are able to produce endospores: the Bacilli, which includes the 
extensively studied model organism Bacillus subtilis, and the Clostridia, to which C. difficile 
belongs. The development of new tools that allow the genetic manipulation of C. difficile, 
together with transcriptomic and proteomic analysis, provided insight onto the composition 
and structure of the spore, and onto the spore differentiation process [47–54]. Sporulation 
proceeds through a series of well-defined morphological stages that culminates about 8 
h after the onset of the process in the production of (usually) one dormant spore per cell 
(Figure 3A) [55–58]. The morphological steps of the sporulation process observed in B. sub-
tilis are conserved in C. difficile [53]. Sporulation begins with a vegetative cell that contains 
two copies of the chromosome which becomes condensed to form a single filament stretch-
ing along the long axis of the cell. An asymmetric division then partitions the cell into a 
small forespore and a larger mother cell (Figure 3A). At this stage, the two cells lie side by 
side. Asymmetric division traps about 30% of one chromosome in the forespore, while the 
remaining of the chromosome is pumped into the forespore following division. Later, the 
mother cell engulfs the forespore to produce a free protoplast isolated from the external 
medium (Figure 3A). The engulfed forespore is separated from the mother cell cytoplasm 
by a system of two membranes that derive from the septal membranes. Next, the engulfed 
forespore is surrounded by two peptidoglycan (PG) layers, the primordial germ cell wall 
(PGCW) and the cortex, and by proteinaceous surface layers (see subsequent text). At this 
point, the spore becomes phase bright (Figure 3B) and develops full resistance to physical 
and chemical agents. At the end of the differentiation process, the mother cell lyses to release 
the mature spore. At the transcriptional level, the process is controlled by a cascade of cell 
type-specific alternative RNA polymerase sigma factors [55, 56, 59] (Figure 3A). Cell type-
specific gene expression and single-cell analysis of transcription and protein localization 
have been monitored in C. difficile using oxygen-insensitive fluorescence-based reporters 
(reviewed in Ref. [60]).
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1.4. Spore functional morphology
The basic endospore architecture is conserved across species. Transmission electron micros-
copy (TEM) shows three main concentric compartments (the core, cortex and surface layers) 
(Figure 3C) [53]. The core contains the bacterial chromosome compacted by the action of 
small acid-soluble spore proteins (SASPs) that can bind to the DNA altering its conformation 
[61]. These proteins provide resistance to damaging factors such as dry heat, UV mutagen-
esis, nucleases, chemicals and desiccation [62]. Immediately juxtaposed to the inner spore 
Figure 3. Sporulation in C. difficile. A: At the onset of the process, the rod-shaped cells divide asymmetrically to produce 
a larger mother cell and a smaller forespore (the future spore) (a). Asymmetric division involves PG synthesis within 
the septum. The mother cell then starts to engulf the forespore (b), eventually releasing it as a free protoplast inside 
its cytoplasm (c). PG polymerization contributes to the engulfment process. Following engulfment completion, the 
forespore is no longer in contact with the external medium and is separated from the mother cell by a system of two 
membranes that derive from the asymmetric division septum. Following engulfment completion, the forespore becomes 
visible as a phase dark body inside the mother cell (d). Synthesis of the primordial germ cell wall takes place from 
the forespore, whereas synthesis of the spore cortex PG layer is a function of the mother cell (see also insert in Figure 
4). Development of full spore refractility coincides with the formation of cortex. Finally, the coat and exosporium are 
assembled (e). The spore is released into the environment through autolysis of the mother cell (f). B: Phase contrast 
microscopy and fluorescence microscopy of a C. difficile vegetative (top) and a sporulating culture (middle and bottom 
panels). For the sporulating culture, at a late stage in spore morphogenesis, the population consists of free spores (a) 
and refractile spores still inside the mother cell (b). The refractile spores exhibit most of the resistance properties of the 
released spores. In the bottom panel, the cells were stained with DAPI (a DNA dye) and the membrane dye FM4-64, 
which stains the developing spore and also the free spores (c). Scale bar, 1 µm. C: transmission electron microscopy 
(TEM) image of a thin cross section of a C. difficile spore. The main spore structures are labelled in the diagram. Note 
that an exosporium-like layer is not visible in the microscopy image, but its position, at the edge of the outer coat, is 
indicated in the diagram. The panel on the right shows a magnification of the spore surface. The diagram identifies the 
main structures or compartments normally seen by TEM. Scale bar, 0.2 µm.
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 membrane that delimits the core is the PGCW, whose composition is similar to the vegetative 
cell wall and serves as a primer for the assembly of the cell wall by the newly formed cells that 
result from spore germination [63]. The cortex is a more external layer formed by a special-
ized PG, essential for the maintenance of the dehydrated state of the spore core, spore miner-
alization, heat resistance and dormancy [46]. While the formation of the PGCW is controlled 
from the forespore, the assembly of the cortex is mainly a function of the mother cell [64, 65]. 
Surrounding the cortex is a proteinaceous coat layer. The coat consists of an inner layer and an 
electron-dense outer layer (Figure 3C). Enzymes constitute an important part of the identified 
coat-associated proteins and are responsible for the enzymatic activities present at the surface 
of spores and which contribute to protection against chemical and physical agents (such as 
organic solvents, oxidative agents and UV light) [46, 50, 64]. The coat also protects the cortex 
layer from the action of PG-breaking enzymes, and has an important role in the interaction of 
spores with germinants, abiotic and biotic surfaces [64, 65]. In some pathogens, an additional 
layer, termed exosporium, surrounds the coat [64, 66]. The exosporium contributes to spore 
protection, acts as a selective permeability barrier and modulates germination through the 
action of associated enzymes and interactions with host cells [64, 66]. In C. difficile, the pres-
ence of an exosporium-like structure remains a matter of controversy; several reports suggest 
that this layer is fragile and easily lost [50, 67], whereas other reports indicate that it is a sta-
ble layer which is only removed by proteases and/or sonication [68–71]. The morphology of 
the exosporium-like layer is strain dependent; some strains have an electron-dense, compact 
exosporium-like layer attached to the coat, whereas others have a hair-like exosporium-like 
layer [58, 71, 72]. C. difficile has three paralogs of a collagen-like glycoprotein, BclA, which in 
the pathogens B. anthracis and B. cereus forms the external hair-like nap of the exosporium 
[66]. In these organisms, BclA forms highly stable trimeric filaments that may contribute to 
spore rigidity; it mediates interactions with host cells and spore uptake, and an immune-
modulatory mechanism that promotes spore persistence [66]. Spores of a C. difficile bclA1 
mutant germinate faster presumably because of increased accessibility of germinants to their 
receptors, but fail to colonize mice; thus, proper assembly of the spore surface is essential for 
colonization of the mouse gastrointestinal tract [73]. While sporulation by C. difficile in vitro is 
highly asynchronous and is completed after days of incubation, sporulation genes are quickly 
induced following inoculation of germ-free mice [74]. Further emphasizing the importance 
of the spore surface layers, the most highly expressed gene in vivo following inoculation of 
germ-free mice, cdeM, codes for a component of the spore surface layers, and an insertional 
cdeM mutant shows impaired colonization [70, 74].
1.5. Spore germination and outgrowth
To cause disease, the dormant C. difficile spores must germinate in the host gastrointestinal 
tract. With appropriate environmental stimuli, spores initiate germination leading to the 
resumption of vegetative growth if sufficient nutrients are present. C. difficile responds to 
unique germinants, such as bile salts [35, 75]. While the bile salt cholate (CA) induces spore 
germination, another primary bile salt, chenodeoxycholate (CDCA), has been identified as 
a potent inhibitor of the process [35, 76]. Bile salt levels are influenced by the commensal 
gut microbiota. C. scindens, for instance, has a bile acid 7α-dehydroxylating activity, which 
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converts CA into CDCA and has been implicated in resistance to infection by C. difficile [77] 
(see also the subsequent text) (Figure 2). Upon antibiotic administration, the disruption of the 
microbiota alters the metabolism of these two compounds and the CA concentration becomes 
higher than CDCA, triggering spore germination [78]. Germination induced by the CA deriv-
ative taurocholate (TA) is also enhanced in the presence of amino acids, such as glycine and 
histidine that act as co-germinants [35, 79]. In C. difficile, once germinants reach their recep-
tors, located in the cortex region, the lytic enzymes that hydrolyse the cortex are activated 
[80–82]. Cortex hydrolysis allows the germ cell wall and the inner spore membrane to expand, 
and a massive release of calcium-dipicolinic acid from the core is observed [80, 83]. This leads 
to complete rehydration, enzyme activation, initiation of metabolism, macromolecular syn-
thesis and spore outgrowth, a process during which the spore protoplast is converted into a 
vegetative cell [84, 85].
2. Antimicrobial therapy and the development of C. difficile infection
CDI is paradoxical as it occurs in the setting of antibiotic administration to treat other bacterial 
diseases. The disturbance of the indigenous gut microbiota by antibiotic administration is a 
key component, together with other risk factors, in the susceptibility to CDI.
Although the human gut microbiota is a complex ecosystem consisting of a vast number of 
bacteria, Archaea, viruses, yeast and fungi, the bacterial part of the microbiota is the most 
studied, mainly through metagenomic approaches, and is essentially formed, in healthy 
adults, by anaerobic bacteria belonging to the Bacteroidetes and Firmicutes phyla [86]. This 
ecosystem, which has coevolved with its human host, is essential to health, and is involved 
in many physiological functions, including metabolic transformations and regulation of 
immune responses [87, 88]. On the other hand, the disruption of the gut microbiota (or dys-
biosis), as through antibiotic exposure, is associated with the pathogenesis of both intestinal 
and extra-intestinal disorders [89–91].
2.1. Effect of antibiotics on gut microbiota
Several studies in humans or in mouse models have shown that antibiotics radically alter the 
composition of the colonic microbiota, significantly decreasing the richness and diversity of 
the bacterial community, as well as its metabolic state. Dethlefsen and Relman demonstrated, 
by pyrosequencing of the 16S rRNA gene, that the effect on the human gut microbiota of 
a 5-day treatment with ciprofloxacin was profound and rapid, with a loss of diversity and 
a shift in community composition occurring within 3–4 days of drug initiation [92]. In all 
three individuals involved in the study, the taxonomic composition of the community closely 
resembled its pre-treatment state by 4 weeks after the end of treatment, but several taxa 
failed to recover within 6 months [92]. In parallel, mouse models have shown similar long-
term disturbance to the gut microbiota after the intake of antibiotics. Using pyrosequencing 
targeting the V6 hypervariable region of the 16S rRNA gene, Antonopoulos and co-authors 
showed that an antibiotic cocktail of amoxicillin, metronidazole and bismuth induced a shift 
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in gut microbial community structure, with an increase in Proteobacteria and a decrease in 
the dominant baseline microbial communities of Bacteroidetes and Firmicutes [93]. Another 
study performed on mice and using the same technology targeting the V1-V3 of the 16S 
rRNA gene showed that a single dose of the broad-spectrum antibiotic clindamycin markedly 
reduced the diversity of the intestinal microbiota for at least 28 days, with an enduring loss of 
~90% of normal microbial taxa from the caecum [94]. The extensive duration of the impact of 
clindamycin is consistent with human studies demonstrating that Bacteroidetes species in the 
faecal microbiota are reduced within 2 years following clindamycin therapy [95]. Finally, an 
integrated multi-omics approach, addressing the total microbiota, active microbiota, metage-
nome, metatranscriptome, metametabolome and metaproteome, to evaluate the changes in 
the faecal microbiota of a single patient after β-lactam-treatment, showed that antibiotics sig-
nificantly alter the gut microbial ecology and interactions with host metabolism [96].
2.2. Antibiotics, the gut metabolic state and susceptibility to CDI
CDI is one of the gastrointestinal diseases that occur in the setting of antibiotic administration. 
Indeed, antimicrobial therapy is one of the main risk factors for CDI, as alteration of the gut 
microbiota increases the susceptibility to CDI [94, 97].
This increased susceptibility is directly correlated with the metabolic state of the altered gut 
microbiota. High-throughput metabolomics studies, using proteomics and multiple mass 
spectrometry, performed on microbiome after antibiotic treatments have shown that antibiot-
ics reduce the levels of most products of bacterial metabolism (such as secondary bile acids, 
glucose, free fatty acids and dipeptides), while promoting accumulation of their precursors 
(oligosaccharides, sugar alcohols and primary bile acids), reflecting the modified metabolic 
activity of the altered gut microbiome [98, 99].
Cumulative evidence indicates that antibiotic-mediated alteration of the gut microbiome, 
besides reducing competitive indigenous flora, converts the global metabolic profile to one 
that favours C. difficile, both spore germination and growth of the bacteria. Indeed, in vitro and 
ex vivo analyses demonstrate that C. difficile can exploit specific metabolites that become more 
abundant in the mouse gut after antibiotic treatment, including the primary bile acid CA for 
germination, and carbon sources such as mannitol, fructose, sorbitol, raffinose and stachyose 
for growth [98]. Infection by C. difficile results in the induction of genes involved in fermenta-
tion and carbohydrate transport and metabolism [74, 100].
It is interesting to note that an abundant metabolic product resulting from bacterial growth 
in the gut, butyrate, induces the differentiation of colonic regulatory T cells [101]. In addition, 
it is well documented that this compound can decrease intestinal permeability and enhance 
colonic defence barriers by increasing mucin production and antimicrobial peptide levels, 
thus preventing host from infection [102]. Therefore, the decrease or elimination of butyrate 
due to microbiota dysbiosis will impair the intestinal defence barrier and increase osmotic 
load in the intestinal lumen, contributing to CDI susceptibility or occurrence. On the other 
hand, the control of C. difficile toxin A and B genes expression seems to be dependent on 
the bacterium’s nutritional environment. As mentioned above, the main positive regulator of 
toxins expression is RNA polymerase sigma factor TcdR, whose production is influenced by 
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various environmental signals. Regulatory proteins, such as CcpA, CodY, PrdR, SigL and Rex, 
and the Agr quorum-sensing system also play a role in controlling toxin gene expression in C. 
difficile, linking the metabolic and redox state of the cell to virulence [103].
The agr1 locus is present in all sequenced strains of C. difficile and consists of two genes, agrB1 
and agrD1, that direct the production of a thiolactone, also known as the T1 signal, which accu-
mulates extracellularly in a cell density-dependent manner [104, 105]. The T1 signal is required 
for tcdA and tcdB transcription, and when added to cultures, it is sufficient to cause premature 
expression of the toxin-encoding genes, suggesting a key role in regulating toxin production 
during growth [105]. At least some RT027 strains, such as R20191, have a second agr locus, 
termed agr2; in contrast to the agr1 locus which carries only the genes for generation of the 
quorum signal, the agr2 locus carries both the signal generation module and the genes required 
for signal detection (agrC2, coding for a sensor kinase) and transduction (agrA2, coding for a 
response regulator) [105, 106]. The agr1 locus, however, seems essential for the generation of 
the T1 signal even in RT027 strains [105]. It is not known which two component systems are 
involved in T1 signal detection and transduction in strains lacking agr2. Importantly, agrA is 
required for complete expression of the toxin-encoding genes as well as the flagellar regulon, 
and an insertional mutant is impaired in colonization and infection in a mouse model [106]. 
In the agrA2 mutant, decreased expression of the genes coding for three phosphodiesterases 
is likely to stimulate the degradation of c-di-GMP [106], may directly contribute to reduced 
expression of the gene coding for σD and, thus, reduced expression of tcdA and tcdB, in line 
with the observation that the flagellar regulon influences toxin production [107].
CcpA, in particular, binds directly to the regulatory region of several PaLoc genes, including 
(and with greater affinity) to tcdR, exerting glucose-dependent repression of toxin produc-
tion; CodY, which binds branched-chain amino acids and GTP and represses the expression 
of many genes involved in responses to nutrient limitation, also binds directly to the tcdR-
regulatory region [103] (Figure 1A).
Taking butyrate as an example, during infection, C. difficile appears to be able to utilize this 
compound [74], an activator of toxin synthesis, by a yet unknown molecular mechanism, and 
the genes involved in the metabolic pathway converting succinate or acetyl-CoA into butyr-
ate are also regulated by CcpA, CodY and Rex. Thus, these metabolic regulators contribute to 
control the production of TcdA and TcdB by regulating the synthesis of butyrate (reviewed in 
Refs. [103, 108]). C. difficile Spo0A also contributes to the regulation of metabolism and, at least 
in some strains, to toxin production. Indeed, glucose uptake, glycolysis and butyrate produc-
tion are downregulated in a C. difficile spo0A mutant [109]. That butyrate is produced by several 
bacteria of intestinal tract as well, suggesting that C. difficile turns on toxin synthesis when in the 
presence of other butyrate-producing species; this appears paradoxical considering that C. diffi-
cile is only able to colonize the colon when the normal microbiota is compromised. Discovering 
how the bacterium regulates butyrate metabolism and associated toxin production will likely 
unravel new ways of attenuating virulence, as suggested [103, 108]. In all, the direct or indirect 
control of the expression of the toxin-encoding genes by global metabolic regulators suggests 
that virulence is part of a strategy to enhance the availability of nutrient resources [103]. The link 
between the expression of tcdR and flagellar assembly, resulting from the σD-type promoter in 
the tcdR-regulatory region [27, 107] (Figure 1A), may also be viewed in this context. However, 
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while σD drives the production of the toxins, it is unknown whether toxin export coincides with 
flagellar assembly and motility. Elevated levels of c-di-GMP promote, in several bacteria and 
also in C. difficile [110], sessile growth in detriment of motility; in C. difficile, elevated levels of 
c-di-GMP reduce the expression of the gene coding for σD and thus also the expression of tcdR 
and of the PaLoc genes [111] (Figure 1A). Finding an appropriate niche may suppress motility, 
and intracellular TcdA and TcdB may be only exported at this stage; the overlap between toxin 
production and motility, however, requires further investigation.
The link between toxin production and spore differentiation is also unclear. It is unknown 
whether the population of cells that produces TcdA and TcdB coincides with the population 
that enters sporulation, or whether toxin producers and sporulating cells represent distinct 
populations. It is also unknown if and to what extent motility, spore formation and toxin pro-
duction overlap. In any event, some degree of coordination exists between these processes, 
as emphasized by the recent discovery of regulatory protein RstA [112]. RstA represses tran-
scription of the sigD gene, and thus it also curtails toxin production while positively control-
ling sporulation initiation, regardless of the presence of a functional sigD gene [112].
3. The Clostridium difficile peptidoglycan biosynthesis pathway
Peptidoglycan, one of the components present in the bacterial cell wall, is the target of some of 
the more effective antibiotics known. PG is required for cell division, cell elongation and also 
for spore differentiation (asymmetric division at the onset of sporulation, engulfment and 
synthesis of the PGCW and cortex) (Figure 3). We provide an overview of the PG-biosynthetic 
pathway in C. difficile, as deduced from genome information, and we integrate information on 
the structure and synthesis of the PG macromolecule with resistance mechanisms to antibiot-
ics that target this pathway.
PG is a heterogeneous polymer of glycan chains cross-linked by short peptides and is the only 
common polymer of both Gram-negative and Gram-positive cell walls. While Gram-negative 
cell walls are composed by a thin layer of PG located between the cell membrane and the 
outer membrane which is composed mainly of lipopolysaccharides, the Gram-positive cell 
wall, in general, has a thick layer of PG decorated by accessory polymers, such as teichoic 
acids [113, 114]. Secondary cell wall polysaccharides are also present in C. difficile but will not 
be covered here [115]. PG is not only essential for the preservation of cell integrity, as it con-
fers mechanical resistance against pressure, but also has an important role in the maintenance 
of cell shape and anchoring of proteins and other polymers on the cell surface [116, 117].
The polysaccharide chains that form the PG are composed of alternating N-acetylglucosamine 
(GlcNAc) and N-acetylmuramic acid (MurNac) residues linked by β 1→ 4 bonds. The MurNac 
residue has a stem peptide linked to the carboxyl group. The chains are cross-linked through 
the formation of peptide bonds between these stem peptides of alternating strands [114, 117, 
118]. These stem peptides have the sequence L-Ala, D-Glu, meso-diaminopimelate (mDAP), 
D-Ala and D-Ala in all Gram-negative, most cyanobacteria and Bacillus and Clostridia spe-
cies. In several Gram-positive species, however, mDAP is substituted by L-Lys (e.g. in 
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Staphylococcus aureus) [116, 119]. The biosynthesis of PG is divided into three stages: (1) syn-
thesis of the nucleotide precursors UDP-GlcNAc and UDP-MurNAc (cytoplasmic stage), (2) 
synthesis of lipid-linked intermediates (cytoplasmic/membrane stage) and (3) polymerization 
of the PG monomers (cell surface stage) [120, 121] (Figure 4).
Synthesis in the cytoplasm involves the action of six Mur ligases (MurA to MurF) that catalyse 
the formation of UDP-MurNac-pentapeptide from UDP-GlcNAc (Figure 4). In the process, 
UDP-GlcNac is converted to UDP-MurNAc by two sequential reactions catalysed by MurA 
and MurB. Next, the amino acids of the stem peptide are added sequentially to the UDP-
MurNAc residue through the action of MurC, D, E and F. MurC is responsible for the addition 
of the first amino acid which corresponds to an L-Ala. MurD recognizes the UDP-MurNac-L-
Ala and adds the second amino acid (D-Glu). MurE adds the third amino acid, either mDAP 
or L-Lys. Finally, MurF adds the fourth and fifth as a dipeptide D-Ala-D-Ala (D-Ala-D-Ser 
or D-Ala-D-Lac in some vancomycin-resistant organisms; see also subsequent text), leading 
to the formation of UDP-MurNAc-pentapeptide [116, 117, 119, 120]. Both the Alr racemase, 
involved in the formation of D-Ala from L-Ala, and the Ddl ligase, involved in the formation 
of D-Ala-D-Ala, are inhibited by D-cycloserine (see Figure 4).
The membrane stage starts with the transfer of the phospho-MurNAc-pentapeptide moi-
ety from the soluble UDP-MurNAc-pentapeptide to the membrane receptor undecaprenyl 
pyrophosphate (C55-P, also known as bactoprenol), yielding undecaprenyl-pyrophosphoryl-
Mur-NAc-pentapeptide (or lipid I). This transfer reaction is catalysed by the integral mem-
brane protein MraY. In a second step, MurG catalyses the formation of a β 1→4 bond between 
MurNAc and a GlcNAc moiety from a UDP-GlcNac molecule (Figure 4). In vitro selection 
experiments have shown that murG is the site of mutations conferring increased resistance 
to vancomycin (see also subsequent text) [122]. The MurG-catalysed reaction produces the 
PG monomer undecaprenyl-pyrophosphoryl-Mur-NAc-(pentapeptide)-GlcNAc (lipid II). 
Flippases, the partially redundant MurJ and Amj proteins in B. subtilis, then translocate lipid 
II to the trans-side of the membrane [117, 123, 124]. In B. subtilis, a sporulation-specific protein, 
SpoVB, produced in the mother cell under σE control (Figure 3A and Figure 4), most likely 
fulfils the same role during spore formation [125–127]. The MurJ homologue of C. difficile is 
coded for by CD630_10680 while a second flippase (CD630_34980) may be the homologue 
of SpoVB (Figure 4); whether the latter is specifically involved in spore formation and thus 
whether C. difficile relies on a single flippase for growth is presently unknown.
During the cell surface stage, the glycan strands are polymerized and peptide bridges are cre-
ated between adjacent strands. Polymerization occurs through a transglycosylation reaction 
between the C1 from the MurNAc residue of the nascent strand and the C4 from the GlcNAc 
residue of the lipid II-linked precursor. Cross-linking of the glycan strands generally occurs 
between the D-Ala at position 4 of the stem peptide and the mDAP (or L-Lys) at position 3 
of a stem peptide from an adjacent strand. This reaction is catalysed by the transpeptidase 
domain present in all PBPs that are able to cleave the D-Ala-D-Ala bond of the stem pep-
tide, releasing the last D-Ala residue, which energizes the transpeptidase reaction [117, 128]. 
The undecaprenyl-pyrophosphate is translocated back to the inner side of the membrane and 
recycled, to receive a new UDP-MurNAc-pentapeptide molecule [121, 128] (Figure 4). Until 
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recently, the transglycosylation reaction has been almost exclusively attributed to the action 
of Class A PBPs (containing a transglycosylation domain; see subsequent text; see also Figure 
5A). Some bacteria, however, lack Class A PBPs, whereas others are able to survive without 
their Class A enzymes [129–132]. The very recent demonstration that integral membrane pro-
teins of the SEDS family (shape, elongation, division and sporulation) [133] have transglyco-
sylase activity solved the paradox [134–136]. In fact, in B. subtilis, RodA (a SEDS protein) is 
a transglycosylase that associates with the complex responsible for PG synthesis during cell 
elongation [128, 134] (Figure 4). In B. subtilis, a RodA paralog, FtsW, has an equivalent func-
tion during cell division and a third protein, SpoVE, is specifically required for the synthesis 
of the spore cortex. SEDS proteins functionally cooperate with elongation- or division-specific 
Class B PBPs (transpeptidases). In B. subtilis, the direct interaction between SpoVE and SpoVD 
(a sporulation-specific transpeptidase) is essential for the formation of the spore cortex and 
spore heat resistance [125, 137] (see also Figure 4).
Homologues of all the enzymes involved in the cytoplasmic membrane and extracytoplasmic 
steps of PG biosynthesis are found in the C. difficile genome (Figure 5). Some important dif-
ferences in the final structure of the PG do exist, however. Firstly, up to 93% of the GlcNAc 
residues are N-deacetylated while no modifications are found in MurNAc [115, 138, 139]. 
Figure 4. Overview of the C. difficile peptidoglycan biosynthetic pathway. The C. difficile counterparts of the genes 
known to intervene at the represented steps in the pathway are highlighted (the ORF code for strain 630∆erm is used). 
No cytoskeletal proteins are drawn for simplicity. The boxed complex, the core of which is formed by a SEDS-type 
transglycosylase (active site on the extracytoplasmic side of the membrane represented by a red dot) and a Class B PBP 
may function in elongation or division, depending on the functions of the represented proteins, which remain to be 
determined. Synthesis of the spore cortex PG follows a similar pathway but may involve sporulation-specific proteins, 
including a complex between a SEDS-type transglycosylase, SpoVE, and SpoVD, a Class B PBP (insert; IFM, inner 
forespore membrane; OFM, outer forespore membrane); SpoVB may be a mother cell-specific flippase. The direction of 
synthesis of the cortex (Cx) and the primordial germ cell wall (PGCW) is shown by arrows. Steps blocked by selected 
antibiotics are shown; the site of action of 654/a is also shown although this compound is a specific inhibitor of the 
SEDS protein RodA of B. subtilis. TM, transmembrane domain; TGase, transglycosylase domain; TPase, transpeptidase 
domain.
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N-deacetylation of GlcNAc has been documented in other Gram-positive bacteria such as 
B. subtilis, B. anthracis, Listeria monocytogenes and Streptococcus pneumoniae and confers resis-
tance to cleavage of the β 1→ 4 bonds between MurNAc and GlcNAc by a muramidase (lyso-
zyme), a first-line defence of the host innate immune response [140, 141]. N-deacetylation 
is achieved through the action of deacetylases such as PgdA from S. pneumoniae [140]. In 
C. difficile, complete resistance to lysozyme involves the extracytoplasmic sigma factor σV, 
which is induced by lysozyme, and leads to further PG deacetylation [139]. Importantly, dis-
ruption of the gene coding for σV (csfV) results in a strongly attenuated mutant in a ham-
ster model of CDI. The pdaV gene (CD630_1556) codes for a protein with homology to PG 
Figure 5. Class A and B penicillin-binding proteins of C. difficile. A: General structure of high- and low-molecular-
weight (HMW and LMW) penicillin-binding proteins (PBP´s). TM, Transmembrane domain; TGase, transglycosylase 
domain; TPase, transpeptidase domain; DD-Pep, DD-carboxypeptidase. B: The amino acid substitutions in PBP1 and 
PBP3 of C. difficile shown in red (A555T and Y721S) have been found in clones with increased resistance to imipenem, 
a carbapenem. The substitutions are indicated relative to the sequence found in a susceptible strain, such as the widely 
used laboratory strain 630∆erm. The groups of residues shown below the black lines form the TPase catalytic site, with 
the numbers indicating the position relative to the N-terminus of the protein. These mutations may confer resistance by 
decreasing the affinity of the enzyme for the antibiotic. The amino acid residues are represented in a single letter code. C: 
The genes coding for the four HMW Class A and B PBPs of C. difficile and the gene coding for the MurJ flippase and their 
genomic contexts. Note that the proteins most similar to the products of CD630_07810, CD630_12290 and CD630_11480 
are PBP1, PBP2 and PBP3 of B. subtilis, respectively. CD630_26520 and CD630_26560 are labelled as spoVE and spoVD, as 
they occupy similar relative positions in the dcw cluster of B. subtilis. B. subtilis has two other SEDS proteins, FtsW and 
RodA that function specifically in cell division and cell elongation, respectively, while SpoVE is involved in the synthesis 
of the cortex PG during sporulation. Since C. difficile only has two SEDS proteins, it is likely that CD630_26520 supports 
cortex synthesis and either elongation or division. SpoVD is also specifically involved in the synthesis of the spore cortex 
in B. subtilis and possibly also in C. difficile. D: growing cells of C. difficile were labelled with Bocillin 650/665 Penicillin 
and with the membrane dye MTG and imaged by fluorescence microscopy; the bottom panel is the merge between 
the images collected in the red (Bocillin 650/665 Penicillin) and green (MTG/Membrane) channels. Note the labelling 
of both the division septa and the lateral wall of the cell. Scale bar, 1 µm. The bottom panel shows the SDS-PAGE and 
fluorimaging analysis of extracts prepared from the labelled cells. At least 10 bands are detected, although some may 
be stable proteolytic fragments of higher molecular weight species (bands a-i). Additional experiments are required to 
assign the bands detected to a specific PBP.
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deacetylases and is itself under the control of σV; the expression of pdaV from an inducible 
promoter bypasses the requirement for csfV for lysozyme resistance and increased the level 
of N-deacetylated GlcNAc [139]. Thus, PdaV is a PG deacetylase, and complete resistance to 
lysozyme is required during infection. C. difficile codes for nine other putative PG deacety-
lases; of those, only CD630_32570 was upregulated in vivo (as compared to growth in vitro) 
during infection in C. difficile-monoassociated mice [74]. Another characteristic of the C. diffi-
cile cell wall PG is that mDAP is found at the third position of the stem peptide. While most of 
the peptide bridges in bacteria are made between the D-Ala residue (fourth position) and the 
mDAP residue through the action of D-D-transpeptidases, approximately 73% of the cross-
links in the C. difficile PG occur between mDAP residues of adjacent strands, through 3→3 
bonds catalysed by L-D-transpeptidases [138, 142]. Two L-D-transpeptidase homologues, 
termed LdtCD1 (CD630_29630) and LdtCD2 (CD630_27130), were shown to participate in these 
reactions; a third homologue (CD630_30070) is likely to be involved because disruption of 
either ldt gene reduces but does not eliminate 3→3 cross-linking [138]. That β-lactams, but 
not carbapenems, inhibit D-D- but not L-D-transpeptidases may be part of the reason why 
C. difficile is tolerant to high concentrations of these antibiotics [115, 138, 142]. Nevertheless, 
while the L-D-transpeptidation pathway is insensitive to ampicillin, C. difficile is susceptible 
to this drug. This suggests that D-D-transpeptidation is important for the overall assembly of 
the PG [138], perhaps explaining the susceptibility of C. difficile not only to β-lactams. Thirdly, 
while most species have D-Ala-D-Ala at the end of the stem peptide, a significant fraction 
of the tetrapeptides ends with a Gly [138]. Intriguingly, while at least the prevalence of the 
L,D-transpeptidation pathway and the reduced presence of D-Ala-D-Ala-ending stem pep-
tides could in principle contribute to vancomycin resistance, C. difficile is susceptible to this 
antibiotic. Moreover, C. difficile carries a vanG-type operon (vanGCD) most similar to that of 
E. faecalis. The van operon codes for enzymes that synthesize PG precursors ending in D-Ser 
or D-Lac and others that eliminate the natural (D-Ala) precursors; it thus confers vancomycin 
resistance [115, 142, 143]. The van operon of C. difficile is inducible by vancomycin and causes 
synthesis of UDP-MurNAc-pentapeptides ending in D-Ser [144]; yet, genetic ablation of the 
van operon in C. difficile, reduced the vancomycin MIC only slightly (from 1.5 to 0.75 mg/l) 
[143]. One possibility is that the incorporation of D-Ala-D-Ala into PG precursors is always 
favoured by the MurF enzyme [143]. Also noteworthy, deletion of the dlt operon, involved 
in D-alanylation of wall teichoic acids, also reduced the vancomycin MIC slightly (from 1 to 
0.75 µg/ml for the strain used) [145]. Conversely, reduced susceptibility of C. difficile to van-
comycin has been observed but the underlying mechanism is unknown [146, 147] (Table 1).
3.1. Penicillin-binding proteins
PBPs belong to a superfamily of acyl serine transferases that bind β-lactam antibiotics through 
a transpeptidase/carboxypeptidase domain which is thereby inactivated. These proteins can 
be divided as high-molecular-weight (HMW) PBPs and low-molecular-weight (LMW) PBPs 
[117, 128] (Figure 5A). The HMW PBPs are multimodular proteins responsible for the insertion 
of new molecules in the PG and cross-link formation. Generally, they contain an N-terminal 
cytoplasmic tail, a transmembrane anchor and two extracytoplasmic domains joined by a 
linker. One of the extracytoplasmic domains has transpeptidase activity responsible for the 
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Antibiotic Mechanism of action Relevance in CDI Resistance frequency Mechanism of 
resistance
Metronidazole DNA damage 
after reduction of 
metronidazole inside 
the bacterial cell
Used in treatment of 
mild/moderate CDI
Rare; reduced 
susceptibility 
reported in frequent 
ribotypes
Multifactorial; 
5-nitroimidazole 
reductase and 
modifications in 
multiple proteins 
involved in DNA 
repair, iron uptake 
and metronidazole 
reduction (putative)
Vancomycin Inhibits cell wall 
synthesis by binding 
to the dipeptide 
D-Ala-D-Ala of 
peptidoglycan 
precursors
Used in treatment of 
severe and recurrent 
CDI
Rare Mutations in murG 
(putative)
Fidaxomycin Inhibition of RNA 
synthesis by binding 
to RNA polymerase 
(in a site distinct from 
rifamycins)
Used in treatment of 
severe and recurrent 
CDI
Rare Mutations in 
rpoB, rpoC and 
rarR (reduced 
susceptibility in in 
vitro mutants)
MLSB Inhibition of protein 
synthesis by binding 
to 23S rRNA
Associated with high 
risk for CDI
High Target protection by 
ermB, localized in 
the elements Tn5398, 
Tn9164 and Tn6215, 
or cfr, localized in 
Tn6218
Fluoroquinolones Inhibition of DNA 
synthesis by binding 
to DNA gyrase and 
topoisomerase IV
Associated with high 
risk of CDI; resistance 
contributed to spread 
of the epidemic 
ribotype 027
High; associated 
with frequent and 
epidemic ribotypes
Target modification 
by mutations in gyrA 
and gyrB
Rifamycins Inhibition of RNA 
synthesis by binding 
to RpoB
Used adjunctively 
for the treatment of 
recurrent CDI
Common; associated 
with frequent 
ribotypes
Target modification 
by mutations in rpoB
Tetracyclines Inhibition of protein 
synthesis by binding 
to 30S ribosomal 
subunit
Resistance found 
in multiresistant 
isolates; resistance 
shared between 
human and swine 
isolates
Common Target protection by 
tetM, carried by the 
elements Tn5398 or 
Tn916-like
Chloramphenicol Inhibition of protein 
synthesis binding to 
the 50S ribosomal 
subunit
Resistance associated 
with prevalent 
ribotypes
Uncommon Inactivation of the 
antibiotic by catD, 
carried by Tn4453 
elements
CDI – Clostridium difficile infection.
Table 1. Summary of Clostridium difficile resistance to antibiotics and associated mechanisms.
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cross-link of adjacent stem peptides. This domain is localized in the C-terminal and has three 
specific motifs that compose the active site: SXXK, (S/Y)XN and (K/H)(S/T)G (Figure 5A). The 
other extracytoplasmic domain is variable and allows sorting of these PBPs in two classes 
[128, 148]. Class A HMW PBPs are called bifunctional PBPs since they have a transglycosylase 
domain, which catalyses the polymerization of the new glycan strands. Transglycosylation 
can occur without a functional transpeptidase domain, but inactivation of the first impairs the 
transpeptidase activity [121, 149]. Class B HMW PBPs have instead another domain proposed 
to play a role in interactions with additional components of the PG synthesis machinery, such 
as a SEDS protein [121, 128, 149].
The LMW PBPs are DD peptidases that in the majority of the cases catalyse DD-carboxypeptidase 
reactions in the D-Ala-D-Ala motifs. Contrary to the HMW PBPs, these proteins are bound 
to the membrane through a C-terminal-located transmembrane domain or an amphipathic 
helix. The catalytic domain is localized in the N-terminal. The LMW PBPs play a role in regu-
lating the degree of PG cross-linking since removal of the carboxy-terminal residue of the 
stem peptide prevents the cross-linking [117, 128, 144].
The number of PBPs and the proportion of the different types vary among different species 
and cell shapes. The rod-shaped spore-forming B. subtilis has 16 PBPs: four of Class A, six of 
Class B and six LMW PBPs. S. aureus, a coccus, has only four PBPs: one Class A, two Class B 
and one LMW. β-lactam resistance of methicillin-resistant strains of S. aureus (MRSA), how-
ever, stems from the acquisition of an extra, low-affinity PBP, PBP2a [117, 128, 134, 150]. It has 
been suggested that rod-shape species have more PBPs in order to be able to synthesize new 
PG not only during cell division, as in cocci, but also during cell elongation. Spore-forming 
species additionally have to synthesize the spore germ cell wall and cortex [150, 151].
C. difficile has nine PBPs identified of which only one is of Class A, three of Class B and five 
LMW PBPs (Figure 5C and Table 2). Note that the numbering of the C. difficile PBPs used 
herein is based on the nomenclature used in a recent study [152]. Strain M68, a recent represen-
tative of RT017 [153], has an additional Class B PBP, referred to as PBP5, which may have been 
recently acquired by horizontal gene transfer. Labelling of exponentially growing cells with 
a fluorescent derivative of penicillin (Bocillin 650/665 Penicillin) shows labelling of both the 
lateral wall of the cell and the division septum, as seen for several other rod-shaped bacteria 
(Figure 5D). Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analy-
sis of whole-cell extracts prepared from the labelled cells followed by fluorimaging reveals a 
collection of 11 labelled bands; although some of these bands may correspond to stable degra-
dation products, the pattern is generally consistent with the genomic information (Figure 5D).
Like S. aureus, C. difficile has only one gene coding for a bifunctional PBP in a monocistronic 
operon (PBP1; CD630_07810). The genes coding for the three Class B PBPs are CD630_12290 
(PBP2), CD630_11480 (PBP3) and CD630_26560 (SpoVD). The gene coding for PBP2 is also 
monocistronic. The gene coding for PBP3 is the last gene of an operon that codes for the 
MreB2 and MreC components of the cell shape/elongation machinery suggesting constitu-
tive production of the protein and a possible involvement in cell elongation. As in B. subtilis, 
spoVD is located within a region containing several other cell division and cell wall genes, the 
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dcw cluster that also codes for the SEDS-type cortex-dedicated transglycosylase SpoVE. It is 
not known whether the SpoVD homologue of C. difficile is also cortex-specific, as in B. subtilis. 
The dcw gene CD630_26520 codes for a SEDS protein and occupies the position homologous 
to that of spoVE in the dcw cluster of B. subtilis (Figure 5C). Since C. difficile only codes for two 
SEDS members, it is unclear whether CD630-26500 is a functional homologue of spoVE and 
whether it accumulates a role in spore cortex synthesis with a vegetative function, in either 
division or elongation. Among the LMW PBPs, it is worth noting that the putative carboxy-
peptidase coded for by CD630_16270 is a homologue of proteins able to confer vancomycin 
resistance (see earlier text).
3.2. Bacterial shape and peptidoglycan synthesis
PG is responsible not only for resistance against physical and chemical stress but also for 
the maintenance of cell shape. In nature, a wide diversity of bacteria shape exists, ranging 
from spheres (cocci) to rods (bacilli), that has been historically used for the characterization 
and classification of species [154, 155]. Cell shape is defined by the different PG synthesis 
apparatus present in the bacteria that, through interaction with cytoskeletal elements, define 
the points where newly synthesized PG is inserted. Cell shape changes through the addi-
tion of antibiotics that inhibit specific complexes or by mutations that inactivate critical com-
ponents of cytoskeleton or PG-biosynthetic machinery [156]. Rod-shaped bacteria have two 
distinct multi-protein complexes driving PG synthesis: the elongasome and divisome. The 
elongasome is responsible for the synthesis of PG in the lateral wall, whereas the divisome is 
Class Gene Protein N° aa kDa
A CD630_07810 PBP1† 897 96.5
B CD630_12290 PBP2† 554 62.6
B CD630_11480 PBP3† 992 111.3
B CD630_26560 SpoVD 659 73.2
LMW D-D-
Carboxypeptidase
CD630_05150 - 409 45.5
LMW D-D-
Carboxypeptidase
CD630_12910 DacF* 387 41.9
LMW D-D-
Carboxypeptidase
CD630_16270 VanY* 268 31.7
LMW D-D-
Carboxypeptidase
CD630_21410 - 397 44.5
LMW D-D-
Carboxypeptidase
CD630_24980 DacF* 429 48.2
†Nomenclature according to Ref. [152].
*Nomenclature according to the NCBI (https://www.ncbi.nlm.nih.gov/gene).
Table 2. The penicillin-binding proteins of Clostridium difficile.
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 assembled for the synthesis of the septal PG during cell division. In general, cocci only syn-
thesize new PG during cell division [151, 154, 157].
Among elongasome components are MreB, MreC, MreD, RodA, RodZ, a Class B PBP and/
or a Class A PBP. MreB is an actin homologue that assembles into short filaments that move 
independently perpendicular to the long axis of the cell, and is the key element that spatially 
governs activity of the elongasome (reviewed in Refs. [149, 158, 159]). MreC and MreD are 
integral membrane proteins of unknown function and RodZ connects MreB with the synthe-
sis machinery [104, 119, 135–138].
Two actin homologues, MreB2 (CD630_10225) and MreB (CD630_01270), are found in C. dif-
ficile. Interestingly, the last gene of the mreBCD operon codes for PBP3 suggesting the par-
ticipation of this Class B PBP in lateral cell wall synthesis. Elongasome complexes include a 
SEDS-type transglycosylase that interacts directly with a class B PBP [149, 158]. In the case of 
C. difficile, the core of the elongasome may include PBP3 and the SEDS protein might be the 
RodA homologue MrdB (coded for by CD630_11520); this gene distances 1.9 kb from the pbp3 
gene, that is, within the genetic distance range identified by Meeske et al. for SEDS/Class B 
PBPs pairs [134]. The only Class A PBP codified by the genome, PBP1 (CD630_07810), may 
also be part of the elongasome. Remarkably, RodZ, thought to help linking MreB to the mem-
brane and to extracytoplasmic complexes [158], is absent in C. difficile.
Among the divisome components in model organisms such as B. subtilis and Escherichia coli 
are FtsZ, FtsA, ZipA, DivIB, DivIC (also referred to as FtsQ and FtsB in E. coli), FtsL, FtsW, a 
Class B PBP and/or a Class A PBP. FtsZ is a tubulin homologue that organizes PG synthesis 
during cell division [121, 149]. FtsZ is tethered to the membrane by proteins such as FtsA and 
ZipA. In E. coli and in B. subtilis, the formation of the Z-ring at midcell relies on two main sys-
tems. In E. coli, the MinCD inhibitor oscillates from pole to pole through the action of MinE, 
causing the overall concentration of the inhibitor to be maximal at the poles and minimal at 
midcell, while in B. subtilis, from which MinE is absent (as is the case of most Gram-positive 
species), MinCD is sequestered at the poles [161]. In both organisms, nucleoid occlusion only 
allows polymerization in areas not occupied by the chromosome (reviewed in [161]). The 
conjugation of the two systems restricts Z-ring formation to midcell. FtsW is a cell division-
specific SEDS glycosyltransferase [151, 160–162].
Benzamides or derivatives of the alkaloid berberine are among the compounds that block 
FtsZ function leading to filamentation [163–165]. Importantly, benzamides showed efficacy in 
a mice model of systemic S. aureus infection [163, 164].
The main components of the divisome complex are found in the C. difficile genome with a 
genetic organization similar to B. subtilis. In B. subtilis, however, ftsZ is co-transcribed with 
ftsA downstream from the mur genes and divIB, whereas divIC is organized in an operon 
upstream from spoIIE and ftsL is co-transcribed with mraW and pbdB (Class B PBP). In C. dif-
ficile, ftsZ (CD630_26460) is downstream from divIB (CD630_26500), but surprisingly, no ftsA 
gene is found in its vicinity or elsewhere in the genome. How FtsZ is tethered to the mem-
brane in the absence of FtsA is unknown. DivIC (CD630_34920) is also upstream from spoIIE, 
required for proper division and cell type-specific activation of σF at the onset of sporulation 
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(see Figure 3A). No ftsL or ftsW genes were identified in the genome, however; as discussed 
above, it is possible that the CD630_26520 gene participates both in cortex synthesis and in cell 
division (Figure 4). The absence of class B PBP and of a SEDS protein in the vicinity of these 
genes may indicate that PBP1 may play a crucial role also in cell division. Between the pbp3 
and mrdB genes is the minCDE operon. This genetic organization is reminiscent of B. subtilis, 
where the mreBCD and minCD genes are co-transcribed [156]. Remarkably, however, the pres-
ence of minE in C. difficile suggests that polar division is controlled through oscillation of a 
MinCDE complex. Finally, a gene cluster coding for three cell division proteins called MldA, 
B and C (midcell-localizing division proteins) can only be found in C. difficile and closely 
related species; mutants lacking MldA and MldB loose the rod-shape and daughter cells sepa-
ration is inefficient [166].
In addition to the elongasome and divisome complexes, generally found in rods, spore-
forming bacteria, like B. subtilis, usually contain a third PG-synthesizing complex that drives 
biogenesis of the spore cortex and the core of which is formed by SpoVE and SpoVD homo-
logues, as discussed above [167, 168]. It is likely that such a complex also operates in C. difficile. 
Antibiotics such as bacitracin (which interferes with the dephosphorylation of C55-isoprenyl 
pyrophosphate), fosfomycin (an inhibitor of MurA) and D-cycloserine (which inhibits the ala-
nine racemase Alr and the D-Ala-D-Ala ligase Ddl) block PG synthesis during spore develop-
ment [123, 169, 170].
Several modifications of the cortex PG, as shown by the work in B. subtilis, are function-
ally important. The cortex has a low percentage of cross-links because of the action of D-D-
carboxypeptidases. Approximately 75% of the stem peptides are removed by the DacA, DacB, 
DacC and DacF enzymes, with DacB and DacF playing a more essential role since spores 
from mutant strains lacking these two proteins are unstable and show higher cross-linking, 
higher core water content and decreased heat resistance. C. difficile codes for two DacF-like 
proteins (CD630_12910 and CD630_24980) and mutants unable to produce these proteins may 
show the same type of alterations as suggested from the work in C. perfringens [171, 172]. 
Importantly, about 33% of the MurNAc residues are in the δ-lactam form, a modification that 
requires the concerted action of an amidase and a MurNAc deacetylase [173]. This modifica-
tion allows the cortex PG to be degraded during germination, while the germ cell wall is 
maintained [174]. It is likely that the same modification is found in the cortex of C. difficile but 
its structure has not yet been reported.
4. Antibiotic resistance and the emergence and spreading of epidemic 
Clostridium difficile strains: historical perspectives and changing 
epidemiology
Virtually all antibiotics are associated with CDI, but the higher risk is linked to prolonged 
administration of broad-spectrum agents. Several studies using meta-analyses to examine the 
risk of CDI associated with the various antibiotic classes showed that the strongest and most 
consistent association was with clindamycin (variable odds ratio (OR): 2.86, 16.8 and 20.43), 
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cephalosporins, particularly those of the second and third generation (variable OR: 2.23, 3.20, 
4.47 and 5.68) and fluoroquinolones (variable OR: 1.66, 5.50 and 5.65) [175–177]. In one of 
these studies, the association between CDI risk and fluoroquinolones was modest (OR: 1.66), 
but the authors argued that this was not surprising since this association was more specifi-
cally related to CDI caused by the fluoroquinolone-resistant epidemic strain [177–179]. This is 
consistent with the fact that ciprofloxacin causes a relatively low disruption of the anaerobic 
gut microflora [180]. Carbapenems also increase CDI risk consistently, although with a weak 
association when considered alone (OR, 1.84), but stronger when included in the group of 
cephalosporins/monobactams/carbapenems (OR, 5.68) [175, 177]. Tetracyclines are not associ-
ated with CDI risk (variable OR: 0.91 and 0.92) [175–177].
There are therefore two effects to consider in the association between infection and antibiot-
ics that act synergistically. One is the effect of the antibiotic on microflora imbalance, and 
the other is the increased risk of CDI in a patient taking an antibiotic for which the infecting 
strain is resistant. Indeed, once antibiotic treatment starts, infection with a C. difficile strain 
that is resistant to the antibiotic is more likely while the antibiotic is being administered due 
to the presence of the antibiotic in the gut. When the antibiotic treatment stops, the levels of 
the antibiotic in the gut diminish rapidly, but the microbiota remains disturbed for a vari-
able period of time, depending on the antibiotic. During this time, patients can be infected 
with either resistant or susceptible C. difficile. Accordingly, mounting evidence suggests that 
antimicrobial resistance in C. difficile is a key player in the epidemiology of CDI [181]. For 
clindamycin, the risk of CDI associated with a clindamycin-resistant strain is increased in 
patients receiving this antibiotic [182]. Regarding cephalosporins, to which C. difficile is intrin-
sically resistant, the use of this antibiotic has been identified as a CDI risk factor in hospitals 
for the last decades [181].
More recently, there was a rise in the fluoroquinolone-associated risk concomitantly with 
the emergence and geographical dispersion of a fluoroquinolone-resistant C. difficile strain, 
designated BI/NAP1/027, for restriction endonuclease analysis group BI, pulse-field gel elec-
trophoresis-type NAP1 and polymerase chain reaction ribotype (RT) 027. In addition to the 
high-level resistance to fluoroquinolones, RT027 strains are characterized by the increased 
production of both the TcdA and TcdB toxins, the presence of the binary toxin CDT and the 
presence of a mutation in the gene coding for the anti-TcdR anti-sigma factor TcdC [183]. 
Whole-genome sequencing (WGS) and phylogenetic analysis showed that this strain emerged 
in North America in the early 2000s, soon after acquiring a fluoroquinolone resistance muta-
tion in gyrA, causing higher rates and more severe cases of CDI, and then spread widely lead-
ing to severe healthcare outbreaks also in the UK, continental Europe and Australia [183–185]. 
The link between the emergence of this clone and the use of fluoroquinolones is unequivo-
cal. Indeed, fluoroquinolones were one of the most frequently prescribed antibiotic classes 
in North America during the late 1990s and early 2000s, so that the selective pressure for the 
acquisition and maintenance of fluoroquinolone resistance within healthcare settings during 
this period would have been at its highest [186].
Molecular-based epidemiological studies show a constant changing in the epidemiology of 
CDI. While in early 2000s RT027 was responsible for CDI outbreaks of increased severity, a 
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study from 2008 analysing the epidemiology of C. difficile in Europe, involving a network of 
106 laboratories in 34 countries, showed that RT027 accounted for only 5% of all C. difficile 
isolates, with a great diversity of ribotypes being observed [187]. Notably, in another recent 
multicenter study comprising 482 participating hospitals from 19 European countries, the 
epidemic strain RT027 was the most prevalent (19%), although distinct regional patterns of 
ribotype distribution were seen [188]. In parallel, other ribotypes, of reportedly increased 
virulence, have started to emerge.
More recently, a toxin A-negative, toxin B-positive C. difficile strain, from RT017, has emerged 
in several countries, sometimes to epidemic proportions. In a CDI surveillance study con-
ducted in Poland between 2004 and 2006, RT017 accounted for approximately 40% of the C. 
difficile isolates studied, while in Bulgaria the occurrence of RT017 between 2008 and 2012 
reached 28% [189, 190]. In the Netherlands, one hospital was affected by an outbreak caused 
by both RT027 and RT017 [185]. In Asia, RT017 strains are one of the most prevalent ribotypes, 
particularly in China, Korea and Thailand [191–193].
In Portugal, CDI surveillance based on a network of sentinel hospitals has been carried out 
since 2010, and showed that RT017 is one the most common ribotypes circulating in the coun-
try [194]. In particular, one RT017 clone was shown to be endemic in a hospital from 2012 until 
today, and a different RT017 clone has emerged in another hospital in the beginning of 2016 
(our unpublished data). Despite belonging to different genetic lineages, based on multiple 
locus variable number tandem repeat analysis, both of these clones harbour several genetic 
determinants of antibiotic resistance such as ermB, tetM, and mutations in rpoB and gyrA/gyrB, 
which confer a multiresistant phenotype (see next section for details on antibiotic resistance 
and associated mechanisms). In addition, they were shown to be resistant to imipenem, the 
first antibiotic of the carbapenems class (highly resistant to β-lactamases and widely used 
against drug-resistant Gram-negative bacteria). Through WGS of the endemic clone, we have 
identified two mutations affecting the transpeptidase domain of two penicillin-binding pro-
tein genes (pbp1 and pbp3; see Figure 5A and B). The mutations are therefore likely to be 
associated with imipenem resistance possibly by reducing the affinity of the drug to one or 
both proteins [152]. The emergence of resistance to carbapenems in multiresistant clones of 
C. difficile might lead to the fast spread of these strains in hospital settings, in an analogy with 
the initial spreading of the fluoroquinolone-resistant strains, and thus deserves urgent and 
continuous surveillance.
5. Overview of resistance to different classes of antibiotics and associated 
mechanisms in Clostridium difficile
As previously mentioned, antibiotics play a major role in the development of CDI. Through 
the disruption of the protective gut microbiota, antibiotics promote the conditions for, not 
only, the germination of the C. difficile spores (see earlier text) once the levels of antibiotic in 
the gut start to decrease, but also for the growth of antibiotic resistant C. difficile during the 
treatment, when there are still high levels of antibiotic in the gut. As such, C. difficile strains 
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that are resistant to several classes of antibiotics will have a selective advantage for the devel-
opment of CDI [20]. Both the rates of resistance in C. difficile and the distribution of ribotypes 
vary extensively between countries. However, as a result of antibiotic-selective pressure, the 
most common ribotypes, which include the epidemic strains, are usually the ones present-
ing the highest rates of resistance [146, 188, 195, 196]. Antibiotic resistance in bacteria can 
be due to mutations in specific genes or due to the presence of genes acquired by horizontal 
gene transfer. The mechanisms of resistance are then divided into three main categories: (i) 
modifications of the antibiotic target, (ii) inactivation of the antibiotic and (iii) reduction of the 
intracellular concentration of the antibiotic [197].
5.1. Metronidazole, vancomycin and fidaxomicin
The surveillance of C. difficile susceptibility to the antibiotics used for CDI treatment, that is, 
metronidazole, vancomycin and fidaxomicin [198], is crucial. Resistance to metronidazole and 
vancomycin has been seldom observed but reduced susceptibility is now being reported more 
often [195]. In two recent studies, the MIC90 (the minimum concentration of metronidazole 
necessary to inhibit 90% of the isolates) of metronidazole was of 2 mg/L for both European 
and US strains, while for vancomycin it was of 2 and 4 mg/L, respectively [146, 199]. Reduced 
susceptibility to metronidazole has been observed in some of the most frequent RTs, includ-
ing RT027, RT001 and RT106 [146, 200]. Heterogeneous and unstable resistance to metroni-
dazole has also been described, in which cases the resistance was only observed in primary 
fresh isolates or after exposing the thawed isolates to low concentrations of the antibiotic, also 
depending on the methodology used; this indicates that these heteroresistant populations 
might go undetected during routine susceptibility testing [201]. Reduced susceptibility to 
vancomycin was also observed in two emergent RTs (RT018 and RT356) in the pan-European 
survey [146] and in the epidemic RT027, among US isolates [147]. Although the clinical impact 
of reduced susceptibility to metronidazole in CDI is still not clear, there is evidence of a corre-
lation between reduced susceptibility and recurrent CDI, which is supported by the low con-
centration of metronidazole observed in the gut, unlike vancomycin which is detected at high 
concentrations [202, 203]. As discussed above, the mechanisms of resistance to metronidazole 
and vancomycin in C. difficile remain to be clarified (but see also subsequent text).
Metronidazole enters the bacterial cell by passive diffusion as an inactive prodrug. It is then 
reduced into its cytotoxic active form through the transfer of an electron to the nitro group 
of the drug, forming a nitroso-free radical, which interacts with DNA, inflicting DNA dam-
age and inhibiting synthesis, ultimately leading to cell death [204, 205]. Some studies point 
to a multifactorial mechanism of metronidazole resistance in C. difficile, which includes (i) 
the activity of a putative 5-nitroimidazole reductase, which converts the nitro group of the 
prodrug into its non-toxic amine derivative; (ii) the elevated expression of proteins involved 
in DNA repair, such as the UvrABC excinuclease, exodeoxyribonuclease, endonuclease III, 
endonuclease IV and DNA mismatch repair protein; (iii) alterations in proteins related to iron 
uptake, such as an increased expression and mutations in the ferric uptake transcriptional 
regulator Fur [206, 207], which plays a central role in iron homeostasis by controlling the 
expression of a regulon that includes genes involved in the mitigation of oxidative stress and 
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in redox metabolism [207]; in Helicobacter pylori, point mutations in fur have been shown to 
increase metronidazole resistance by reducing the binding affinity of the modified Fur protein 
to the promoter region of the superoxide dismutase encoding gene sodB and hence rendering 
Fur unable to efficiently repress transcription of sodB; high levels of SodB, in turn, allow H. 
pylori to counteract the oxidative stress generated by the activated metronidazole [208–210]; 
and (iv) alterations in the metabolic pathway involving pyruvate-ferredoxin oxidoreductase 
(Pfo), responsible for metronidazole reduction; a reduced concentration of Pfo, for example, 
will likely lead to a less efficient activation of metronidazole inside the bacterial cell [211].
Vancomycin inhibits bacterial cell wall synthesis by binding to the D-Ala-D-Ala dipeptide of 
the peptidoglycan precursor before cross-linking of adjacent peptidoglycan strands. The in 
vitro selection of isolates with reduced susceptibility to vancomycin showed the acquisition 
of a mutation causing a P108L substitution in murG; since MurG converts lipid I to lipid II, a 
target of vancomycin, it is conceivable that alterations in this pathway might affect the activity 
of vancomycin (see earlier text; Figure 4). Other mutations found included a stop codon in an 
RNA/single-stranded DNA exonuclease (CD630_36590), a single amino acid deletion in the 
sdaB-encoded L-serine dehydrogenase, and a missense mutation causing a D244Y substitu-
tion in rpoC, coding for the β´subunit of RNA polymerase. How mutations in murG, sdaB and 
rpoC and dlt operon contribute to the reduced susceptibility to vancomycin is still unknown 
[122] (Table 1).
Fidaxomicin blocks an initial step in transcription by RNA polymerase. Binding of the RNA 
polymerase holoenzyme to a promoter results in the formation of a closed complex, which is 
isomerized to an open promoter complex through opening of the double-stranded DNA; the 
melted region, or transcription bubble, extends approximately from positions −12 to +2 rela-
tive to the transcription start site [212]. Fidaxomicin inhibits transcription initiation if added 
before the stable holoenzyme/promoter open complex is formed, in contrast with antibiotics 
that inhibit RNA elongation such as the rifamycins [212]. In vitro selection for resistance led to 
the identification of a mutation in the rpoB gene (coding for the β subunit of RNA polymerase) 
causing the single amino acid substitutions Q1074K or Q1073R [122, 213]. Substitutions in the 
β´subunit have also been linked to resistance (R337A) or reduced susceptibility to fidaxomicin 
(two simultaneous substitutions, Q781R and D1127E) [213, 214]. Another mutation associ-
ated with reduced susceptibility to fidaxomicin, selected in vitro, is a frameshift mutation in 
the CD630_22120 gene coding for a homologue of the multidrug resistance-associated tran-
scriptional regulator MarR; the role of this regulatory protein in fidaxomicin resistance is still 
unclear [122] (Table 2). Resistance to fidaxomicin has only been observed in one isolate with a 
MIC of 16 mg/L [215], being that usually all isolates are inhibited at concentrations of ≤1 mg/L 
[146, 199, 216].
5.2. Clindamycin
Clindamycin is one of the antibiotics associated with an increased risk of CDI [177], and resis-
tance to this antibiotic is one of the most common in C. difficile. Clindamycin resistance is often 
found in >30% of the isolates worldwide and frequent RTs tend to exhibit higher rates of resis-
tance. Furthermore, clindamycin resistance is frequently found in multidrug-resistant isolates 
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in association with resistance to fluoroquinolones and rifampicin [146, 192, 199, 216–219]. 
Resistance to clindamycin, a lincosamide that inhibits bacterial protein synthesis by binding 
to the bacterial 23S rRNA, is generally due to the presence of ermB (erythromycin resistance 
methylase gene). The rRNA adenine N-6-methyltransferase encoded by this gene methylates 
the adenine at position 2058 of 23S rRN, which prevents binding of the MLSB (macrolide, lin-
cosamide and streptogramin B) antibiotics. This gene is found in mobile elements, such as the 
transposons Tn5398, which contains two copies of ermB, Tn6194 and Tn6215. These elements 
are horizontally transferred between C. difficile strains and also to and from other genera [220]. 
Even so, there is a significant proportion of clindamycin-resistant C. difficile strains, which are 
ermB-negative [218]. Recently, a cfr-like gene was found to confer resistance to multiple anti-
biotics in C. difficile, including clindamycin/erythromycin, linezolid and chloramphenicol/flor-
fenicol. Like ermB, this gene is found in a transposon, Tn6218, and confers resistance through 
modification of the bacterial 23S rRNA at position A2503 [221, 222].
5.3. Fluoroquinolones
Fluoroquinolones play a major role in the paradigm of CDI. Resistance to this class of 
antibiotics, which inhibit bacterial DNA synthesis by binding to the type II topoisomer-
ases DNA gyrase and topoisomerase IV [223], was associated with the worldwide spread 
of the epidemic RT027 in the 2000s and rapidly became a prominent risk factor for CDI, 
as previously described [224]. Since then, fluoroquinolones resistance has been reported 
worldwide with increasing rates and is frequently found in common and epidemic strains, 
such as those of RT027 (in which the resistance is almost ubiquitous), RT017 and RT018 
[146, 192, 225]. The rates of resistance vary considerably between countries; however, this 
is likely due to differences in ribotype diversity, since the countries with higher diver-
sity of ribotypes tend to exhibit lower rates of fluoroquinolones resistance and vice versa 
[146]. This same trend was observed in Portugal when comparing ribotype diversity and 
resistance rates between regions [194]. Fluoroquinolone resistance in C. difficile, as a result 
of antibiotics use selective pressure, is associated with well-known mutations in the qui-
nolone-resistance determining region of DNA gyrase subunits gyrA and gyrB. Mutations 
causing a T82I substitution in GyrA are the most commonly identified in C. difficile, and 
are found in ribotypes such as RT027 and RT017 [194, 218, 226]. Importantly, resistance to 
fluoroquinolones is likely to be maintained even without antibiotic pressure, as it does not 
impose a fitness cost in C. difficile [227].
5.4. Rifamycins
Rifamycins are a class of antibiotics that inhibit bacterial RNA synthesis by binding to the β 
subunit of RNA polymerase (coded for by the rpoB gene) [228]. Two members of this class, 
rifampicin and rifaximin, have been used adjunctively for the treatment of recurrent CDI, 
despite not being recommended due to the absence of evidence supporting their efficacy (vs. 
monotherapy) [198, 229, 230]. In fact, high rates of rifampicin resistance have been identi-
fied in epidemic strains [231]. In a recent study, rifampicin resistance (13.4%) was reported 
in 17/22 European countries, and although it was observed in several RTs, it was mostly 
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 associated with frequent RTs, such as RT027, RT018 and RT356 [146]. Also, in Portugal, all 
the RT017 strains, a predominant type [194], show high resistance to rifampicin (unpublished 
data). It has been demonstrated that in vitro susceptibility to rifampicin is predictive of rifaxi-
min susceptibility [228] and the emergence of rifamycin resistance during a recurrent C. dif-
ficile infection following rifaximin treatment has been clearly demonstrated [232]. As in other 
bacteria, resistance to this class of antibiotics in C. difficile results from specific substitutions 
in, or near to, the residues in the β subunit of RNA polymerase that interact with rifamycins. 
The substitution R505K is the most frequently found in C. difficile, either alone or along with 
other substitutions, such as the frequently found H502N. Furthermore, the resistant isolates 
do not seem to have a clonal origin but rather appear to arise independently as the result of 
antibiotic pressure [218, 228].
5.5. Tetracyclines
Tetracyclines inhibit protein synthesis in bacteria by binding to the 30S subunit of the bac-
terial ribosome, thereby preventing the association of aminoacyl-tRNA [233]. Tetracycline 
resistance is a relatively common trait in C. difficile. The resistance rates vary widely between 
countries, with some presenting high rates but the majority having <10%-resistant isolates 
[234, 235]. The exposure to tetracyclines, however, does not seem to be associated with an 
increased risk of CDI [177]. Even so, resistance to tetracycline is usually found in multidrug-
resistant isolates, such as those of RT012 and RT017 [218, 234, 235], and is, in most strains, 
associated with the presence of the tetM gene, which codes for a ribosome protection protein. 
This gene is carried by transposons Tn5397, which is found in RT012, and Tn916-like, which is 
found in RTs such as RT017 and RT078 [236]. TetM confers protection by binding to the ribo-
some in the proximity of the tetracycline-binding site and hence dislodging and preventing 
binding of the tetracyclines to their target [237]. Although less frequent, another tet gene, tetW, 
which also codes for a ribosomal protection protein, has been found in tetracycline-resistant 
C. difficile isolated from humans and animals that also harboured the tetM gene [218, 238]. 
Furthermore, the co-presence of tetM and ermB in a Tn916-like element presumably origi-
nated by the recombination of different elements has also been described [239].
Tetracyclines are the most used antibiotics for veterinary purposes [240]. Notably, the high 
homology between C. difficile RT078 isolates from human and swine has been emphasized by 
the common tetracycline resistance determinants found in both groups, strongly suggesting a 
zoonotic spread of C. difficile and resistance [241].
5.6. Chloramphenicol
Chloramphenicol inhibits bacterial protein synthesis by binding to the A-site of the 
50S-ribosomal subunit [242]. Resistance to chloramphenicol is relatively uncommon in C. dif-
ficile, and is found in only 3.7% of the European isolates with a marked variation between 
countries that seem to reflect a localized association with specific RT, namely RT001, that 
apparently spread after acquiring resistance to chloramphenicol [146]. Resistance to this 
antibiotic is usually due to the presence of catD, which encodes a chloramphenicol acetyl-
transferase that catalyses the transfer of an acetyl group from acetyl-CoA to chloramphenicol, 
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thus rendering the antibiotic unable to bind to the ribosome [243], and is carried by a Tn4453 
element [244]. Another gene, cfr, has been found to confer resistance to chloramphenicol 
and also to other classes of antibiotics in C. difficile, as already mentioned earlier (see section 
“Clindamycin”).
5.7. Multidrug resistance in C. difficile
In 2005, 82 of 316 European C. difficile isolates were resistant to at least three antibiotics. The 
predominant phenotype among these strains, which mainly belonged to RT001, RT017 and 
RT012, was multiple resistances to clindamycin, erythromycin, moxifloxacin and rifampi-
cin [218]. More recently, 27.5% of RT027 strains in the US were also multidrug resistant 
[225]. In China, 73.3% of the strains were multidrug resistant and mainly included strains 
from RT017, which is predominant in Asian countries, as discussed earlier [234]. Similarly, in 
2012, 85.5% of Polish strains were multiresistant, being all strains from RT027, RT176 (related 
to RT027), RT012 and RT046 [217]. The recent pan-European study also associates specific 
RT with multidrug resistance, including RT027, RT001 and RT017, which are common RT 
in many countries, but also RT018 and RT356 that are predominant in Italy. Another highly 
resistant RT, RT356, also found in Italy, is resistant to rifampicin, moxifloxacin, clindamycin, 
imipenem and chloramphenicol [146]. Similarly, most of RT017 strains isolated in Portugal 
are resistant to moxifloxacin, clindamycin, erythromycin, rifampicin, tetracycline and imi-
penem (our unpublished data; see also earlier text and Figure 3B); it seems possible that the 
resistance to imipenem arose due to the intense use of carbapenems in Portugal in the last 
decade [245]. The recently described cfr gene in C. difficile, to which we alluded to earlier, is 
another concern since it provides multidrug resistance and the extent of its dissemination in 
C. difficile isolates is still unknown [221]. Notably, most of the ribotypes associated with mul-
tidrug resistance are epidemic and/or associated with increased CDI severity, which hints at 
multidrug resistance constituting a selective advantage for the spread and infective potential 
of these strains. Overall, these data indicate a clear association between prevalent RT and 
multidrug resistance, in line with the view that antibiotic pressure drives the evolution of 
these strains.
6. Novel strategies for treatment and prevention of C. difficile infection
Strategies to neutralize C. difficile target all different stages in the organism´s life cycle. 
Chlorine-based disinfectants are used to reduce the load of spores in contaminated surfaces in 
healthcare facilities [246]. Triggering germination has been proposed as a method to enhance 
the killing of spores that accumulate in healthcare facilities, in combination with UV-C or dis-
infectants [247]. The recent demonstration of sporicidal activity of ceragenin CSA-13 is worth 
mentioning. Ceragenin CSA-13 is a cationic compound that mimics endogeneous antimicro-
bial peptides and shows a wide spectrum of bactericidal activity [248]. When incubated with 
B. subtilis spores, ceragenin CSA-13 appears to disrupt the inner spore membrane, causing 
the release of Ca2+-dipicolinate from the core and loss of spore viability [248]. Although likely, 
activity against spores of C. difficile was not reported.
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Antimicrobial stewardship is an important aspect in strategies designed to prevent and control 
CDI outbreaks, in addition to infection control and containment measures and environmental 
decontamination [229]. The importance of antibiotic stewardship practices is exemplified and 
stressed here by the identification of the pbp1 and pbp3 alleles in imipenem-resistant strains of 
C. difficile (see earlier; Figure 5B). Other reviews provide a detailed discussion on measures 
for the treatment and prevention of CDI [9, 229]. ‘Breakthrough’ approaches in the treatment 
and prevention of CDI fall into three main areas [9]: (i) antibiotic therapies, (ii) biotherapeutics 
and (iii) immunological therapies [9]. We review here some of the approaches in each of these 
broad areas, and also refer to the effect of diet in the control of C. difficile.
6.1. Antibiotics
As the broad-spectrum metronidazole and vancomycin have a considerable impact on the 
microbiota and show high recurrence rates, there has been an intense search for new anti-
microbials of narrower spectrum. The narrow-spectrum antibiotic fidaxomicin, approved 
by the Food and Drug Administration (FDA) in 2011, is an example. It is a macrocyclic non-
systemic antibiotic shown to be highly selective against C. difficile and superior to vancomy-
cin in eliciting a sustained clinical response, that is, cure without disease recurrence [249]. 
Several aspects of fidaxomicin action may contribute to its efficacy. In vitro, the drug pre-
vents toxin production [250], and when added to cultures at the onset of stationary phase, 
fidaxomicin also prevented entry into sporulation [251]. It also prevented the outgrowth of 
cells from germinated spores (it did not prevent the initiation of spore germination, how-
ever) [252]. The inhibition of spore outgrowth and of sporulation may be the main factors 
contributing to the efficacy of fidaxomicin in suppressing disease recurrence and transmis-
sion (Figure 2).
Other narrow spectrum antimicrobials are undergoing clinical trials (www.clinicaltrials.org). 
Surotomycin, also called CB-183,315, is a lipopeptide antibiotic structurally related to dap-
tomycin which is currently in phase III clinical development. As is the case for daptomycin, 
Surotomycin may work by dissipating the membrane potential [253]. In vitro studies showed 
activity of Surotomycin against C. difficile isolates with elevated MICs for metronidazole, 
moxifloxacin and vancomycin but lack of activity against Enterobacteriaceae and species of 
the Bacteroides fragilis group [254, 255], suggesting that it may not cause significant disruption 
of the microbiota.
Another example is Cadazolid. This drug is primarily a protein synthesis inhibitor, but the 
molecule also includes a fluoroquinolone moiety that acts as a weak inhibitor of DNA synthe-
sis at much higher concentrations of the drug [256]. The addition of Cadazolid to stationary 
phase cultures inhibits the production of the TcdA and TcdB toxins and spore formation, 
while in both the hamster and mouse models Cadazolid was as effective as vancomycin [257]. 
Trials suggest that Cadazolid may be as effective as vancomycin, but with lower recurrence 
rates [9].
Ridinilazole [2, 2ʹ-bis(4-pyridyl)3H,3ʹH 5,5ʹ-bibenzimidazole] was more active than fidax-
omicin, metronidazole and vancomycin against C. difficile; it was less effective against other 
intestinal bacteria, including the B. fragilis group, and Gram-positive species of Bifidobacteria, 
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among others [258, 259]. Phase II trials are under way to investigate the efficacy of Ridinilazole 
in comparison to fidaxomicin and vancomycin. The mechanism of action of Ridinilazole has 
not been described. The addition of Ridinilazole to C. difficile cultures at concentrations below 
the MIC results in cell filamentation, however, suggesting that it may act as a cell division 
inhibitor [260].
CRS3123 (formerly REP3123) is a synthetic diaryldiamine that inhibits methionyl-tRNA syn-
thetases and protein synthesis in Gram-positive bacteria [261]. In vitro, CRS3123 inhibits the 
growth of C. difficile and blocks toxin and toxin production when added to stationary phase 
cultures; CRS3123 demonstrated good potency against C. difficile, but was much less active 
against other bacteria of the normal intestinal flora [261–263]. It also proved superior to van-
comycin in the hamster model of CDI [263]. Clinical trials to determine the efficacy and phar-
macokinetics of CRS3123 have been completed but no results are yet posted.
The newly discovered SEDS-type transglycosylases, which appear as promising targets for 
new antibiotics, are worth noting. Screening of a library of actinomycete strains against a 
B. subtilis strain lacking all four Class A PBPs (transglycosylases/transpeptidases) led to the 
identification of a compound, 654/A, that caused large zones of inhibition on plates of the 
indicator strain (but not of the congenic WT) and morphological defects characteristic of 
mutants impaired in cell wall synthesis [136]. Consistent with the possibility that 654/A tar-
gets a SEDS transglycosylase, not only it acted synergistically with moenomycin, an inhibitor 
of the transglycosylase domain of Class A PBPs, but overproduction of the elongation-specific 
SEDS protein RodA mitigated its effects [136]. 654/A was also active against S. aureus. Activity 
against C. difficile was not reported.
6.2. Bacteriotherapies
Among the class of bacteriotherapies are the use of probiotics, spores of non-toxinogenic 
strains, faecal microbiota transplantation (FMT) and precise manipulation of the gut micro-
biota. While a number of probiotic formulations are under clinical testing, evidence for their 
efficacy in the treatment of CDI is presently controversial [9]. FMT, on the other hand, which 
relies on the disruption of dysbiosis in patients undergoing antibiotic treatment, has been 
used with a success rate of over 90% [9]. Difficulties associated with FMT, such as poor repro-
ducibility, availability of the material and patient acceptance, could in principle be solved by 
the identification of the bacteria in faecal material responsible for the beneficial effect. The 
isolated strains could be produced and formulated under controlled conditions and used for 
therapeutic interventions. This quest is supported by several findings. Gut dysbiosis could 
be disrupted by a mixture of six intestinal bacteria (including S. warneri, Enterococcus hirae, 
Lactobacillus reuteri, and three novel species of Anaerostipes, Bacteroidetes and Enterohabdus), 
and this mix could clear infection by a RT027 strain in mice [40]. Also, a defined mixture of 
17 gut-indigenous strains, enriched in Clostridia, isolated from the faeces of healthy humans, 
induced the differentiation of gut-regulatory T cells [264, 265]. A more defined intervention is 
illustrated by the finding that the administration of C. scindens, both in mice and in humans, 
enhances resistance to infection in a secondary bile acid-dependent manner [77]. While the 
depletion of the bile acid-hydroxylating activity of C. scindens caused by antibiotics, and the 
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decreased resistance to CDI clearly illustrates the link between antibiotics, bile acid metabo-
lism and susceptibility to CDI, restoration of secondary bile metabolism may be a key mecha-
nism for the success of FMT in treating recurrent CDI [266, 267]. While these interventions 
rely on the bacteria that are transferred to the compromised host, a very recent report indi-
cates that the transfer of sterile filtrates from donor faeces to patients with a diagnostic of 
CDI is sufficient to eliminate symptoms [268]. The authors of this study suggest that bacterial 
components, metabolites or perhaps phages mimic or substitute for many of the effects of 
FMT [268].
Also in the category of the biotherapeutic approaches to control and prevent CDI is the oral 
administration of spores of non-toxinogenic strains. A strain, NTCD-M3, isolated at high fre-
quency from hospitalized patients asymptomatically colonized, was found to lack the toxin-
encoding genes [269]. Spores produced by NTCD-M3 were given orally to patients under 
metronidazole or vancomycin treatment for their first episode of CDI or first CDI recurrence 
[270, 271]. Colonization was a function of the number of spores given daily. Recurrence was 
lower in patients receiving spores relative to the control group and correlated with coloniza-
tion. Colonization was transient and lost after 22 weeks, perhaps because of the recovery 
of the gut microbiota [270, 271]. Presumably, recurrence was prevented because NTCD-M3 
outcompeted toxinogenic strains and prevented further colonization by the latter strains. The 
exact mechanism, however, is not known. So far, the transfer of the PaLoc from toxinogenic to 
non-toxinogenic strains has only been detected in vitro [272].
6.3. Vaccines
Antibodies directed against the receptor-binding domains of the TcdA and TcdB toxins pre-
vent binding to their receptors and confer protective immunity against CDI in animal models 
and protection against recurrent disease in humans [10, 11]. Three vaccine candidates are 
currently under development for CDI, all of which involve parenteral delivery of toxoids. 
Sanofi has a toxoid vaccine composed of partially purified and formalin-inactivated TcdA and 
TcdB toxins [273, 274]. The Pfizer vaccine contains mutant forms of the TcdA and TcdB toxins 
with mutations thought to abrogate glucosyltransferase and auto-protease activities; residual 
activity of the toxins, however, required pre-incubation of the antigens with specific antibod-
ies or formalin [275]. The Valneva vaccine contains a recombinant fusion protein between the 
receptor-binding domains of both TcdA and TcdB which induced neutralizing levels of serum 
antibodies to both toxins and reduced disease severity while conferring significant protection 
against a lethal dose of C. difficile spores in hamsters [276].
In an alternative strategy, B. subtilis spores were used as a delivery vehicle for the carboxy 
terminal repeat domains of TcdA and TcdB fused to surface-exposed spore coat proteins [277]. 
Oral immunization with spores displaying the TcdA repeat domain alone conferred protec-
tion against challenge with a C. difficile strain producing both toxins, and vaccinated animals 
survived reinfection. Mucosal immunization was required to generate secretory IgA and the 
local production of these neutralizing polymeric antibodies correlated with protection [277]. 
A trial to assess safety and immunogenicity of a spore-based vaccine (CDVAX) started on 1 
January 2017.
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6.4. Diet
Finally, recent work has highlighted a role for the diet in the prevention of CDI. Zn has a 
role in modulating the diversity of the microbiota: mice fed with a high Zn diet showed 
decreased microbiota diversity, as opposed to mice on a low Zn diet [278]. A Zn-binding 
protein, Calprotectin added to C. difficile cultures, prevented growth in a Zn-dependent man-
ner (as a mutant deficient in Zn binding did not prevent growth), and Calprotectin-deficient 
mice showed decreased survival and increased disease severity following challenge with an 
RT027 strain [278].
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